Kevin S Gorski Selected Research

N- (4- (4- amino- 2- ethyl- 1H- imidazo(4,5c)quinolin- 1- yl)butyl)methanesulfonamide

12/2007

First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kevin S Gorski Research Topics

Disease

6	Neoplasms (Cancer) 01/2021 - 07/2006
4	Melanoma (Melanoma, Malignant) 01/2021 - 04/2009
1	Fatigue 09/2017
1	Chills 09/2017
1	Fever (Fevers) 09/2017
1	Inflammation (Inflammations) 05/2014
1	Asthma (Bronchial Asthma) 05/2014
1	Respiratory Hypersensitivity 05/2014
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/2009
1	Primitive Neuroectodermal Tumors (PNET) 12/2009
1	Virus Diseases (Viral Diseases) 07/2006

Drug/Important Bio-Agent (IBA)

3	talimogene laherparepvecIBA 01/2021 - 01/2016
2	Toll-Like Receptor 7IBA 04/2009 - 12/2007
1	AntigensIBA 01/2021
1	B7-H1 AntigenIBA 09/2017
1	pembrolizumabIBA 09/2017
1	CTLA-4 AntigenIBA 01/2016
1	IpilimumabIBA 01/2016
1	Thymic Stromal LymphopoietinIBA 05/2014
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 05/2014
1	AllergensIBA 05/2014
1	CytokinesIBA 05/2014
1	ganitumabIBA 12/2009
1	Toll-Like Receptor AgonistsIBA 04/2009
1	Toll-Like Receptors (Toll-Like Receptor)IBA 04/2009
1	PerforinIBA 04/2009
1	N- (4- (4- amino- 2- ethyl- 1H- imidazo(4,5c)quinolin- 1- yl)butyl)methanesulfonamideIBA 12/2007
1	LigandsIBA 07/2006

Therapy/Procedure

2	Therapeutics 09/2017 - 12/2009
1	Immunotherapy 04/2009